p53 activation by Pl-3K family kinases after DNA double-strand breaks;Activation de p53 par les kinases de la famille Pl-3K apres cassures double brin de l'ADN

Bulletin du Cancer

Volumn 87, Issue 9, 2000, Pages 635-641

  Pernin, D ^a   Uhrhammer, N ^a   Verrelle, P ^a   Bignon, Y J ^a   Bay, J O ^a  

^a NONE

Author keywords

ATM; ATR; DNA damage; DNA PK; p53; Phosphorylation

Indexed keywords

DOUBLE STRANDED DNA; PROTEIN KINASE; PROTEIN P53;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; DNA DAMAGE; DNA STRAND BREAKAGE; GENE ACTIVATION; GENE MUTATION; GENETIC TRANSCRIPTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW;

ACETYLATION; APOPTOSIS; CELL CYCLE PROTEINS; DNA DAMAGE; ENGLISH ABSTRACT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMAN; PHOSPHORYLATION; PROTEIN P53; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 0033793480     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Cancer. p53, guardian of the genome
2. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
3. Molecular interaction map of the mammalian cell cycle control and DNA repair systems
4. Signaling to p53: Breaking the posttranslational modification code
5. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells
6. Participation of p53 protein in the cellular response to DNA damage
7. Evidence for a second cell cycle block at G2/M by p53
8. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis
9. A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain
10. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6
11. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking
12. Signaling to p53: Breaking the MDM2-p53 circuit
13. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins
14. Mdm-2: 'Big brother' of p53
15. Multisite phosphotylation and the integration of stress signals at p53
16. Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2
17. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization
18. DNA damage induces phosphorylation of the amino terminus of p53
19. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
20. Nature of G1/S cell cycle checkpoint defect in ataxia-telangiectasia
21. The role of the ataxia-telangiectasia gene in the p53, WAF1/CIP1(p21)- and GADD45-mediated response to DNA damage produced by ionising radiation
22. Defective induction of stress-activated protein kinase activity in ataxia-telangiectasia cells exposed to ionizing radiation
23. Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms
24. Recruitment of ATM protein to double strand DNA irradiated with ionizing radiation
25. Enhanced phosphotylation of p53 by ATM in response to DNA damage
26. DNA-dependent protein kinase catalytic subunit: A relative of phosphatidylinositol 3-kinase and the ataxia-telangiectasia gene product
27. Mutation of the serine 15 phosphotylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression
28. Rapid ATM-dependent phosphotylation of MDM2 precedes p53 accumulation in response to DNA damage
29. The complexity of p53 modulation: Emerging patterns from divergent signals
30. Insights into the functions of BRCA1 and BRCA2
31. BRCA1 regulates p53-dependent gene expression
32. Requirement of ATM-dependent phosphorylation of brcal in the DNA damage response to doublestrand breaks
33. Role for ATM in DNA damage-induced phosphorylation of BRCA1
34. DNA-dependent protein kinase and related proteins
35. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53
36. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
37. Mdm-2 phosphotylation by DNA-dependent protein kinase prevents interaction with p53
38. Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV
39. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage
40. Enhanced phosphorylation of p53 serine 18 following DNA damage in DNA-dependent protein kinase catalytic subunit-deficient cells
41. Regulation du cycle cellulaire des cellules exposees aux radiations ionisantes
42. cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein
43. A role for ATR in the DNA damage-induced phosphorylation of p53
44. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
45. ATM protein and p53-serine 15 phosphorylation in ataxia-telangiectasia (AT) patients and at heterozygotes
46. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints
47. DNA damage activates p53 through a phosphorylation-acetylation cascade
48. Soft-tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome?
49. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
50. Breast cancer risk in ataxia-telangiectasia (AT) heterozygotes: Haplotype study in French AT families
51. No evidence for constitutional ATM mutation in breast/gastric cancer families
52. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia
53. The SCID mouse mutant: Definition, characterization, and potential uses
54. ATR disruption leads to chromosomal fragmentation and early embryonic lethality
55. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
56. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus
57. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
58. Safety evaluation of Ad5CMV-p53 in vitro and in vivo
59. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
60. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
61. A phase I/II study of hepatic artery infusion with wrp53-CMV-Ad in metastatic malignant liver tumours
62. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
63. Antisense ATM gene therapy: A strategy to increase the radiosensitivity of human tumors
64. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay
65. Wortmanin, an antibiotic produced by Penicillium wortmanni
66. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin